08:53 AM EST - BioVaxys Technology Corp : Announced today that it has entered into an agreement with Millipore-Sigma, a global Contract Development and Manufacturing Research Organization, to manufacture a supply of GLP-grade BVX-1021, the Company's newly developed vaccine for the strain of coronavirus that causes Severe Acute Respiratory Syndrome, the respiratory illness responsible for the deadly 2002–2004 pandemic. Currently there are no vaccines approved for SARS1. BioVaxys Technology Corp
shares C.BIOV are trading down one cent at $0.12.
